On November 4, 2026 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, reported that the Company’s research examining a mechanism of resistance to CAR T-cell therapy and the potential of DNase I to reverse this process has been selected for oral presentation at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting. The conference will take place December 12-15, 2026, in New Orleans, Louisiana, and virtually.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will examine how extracellular chromatin released during CAR T-cell killing establishes a self-reinforcing resistance niche and how DNase I reverses this process. By investigating a resistance mechanism that arises during CAR T-cell killing itself, the research addresses a central challenge in the field: understanding how the response to tumor-cell destruction may create conditions that limit continued treatment activity.
The research will be featured in the session "Overcoming Resistance and Escape in CAR-T Cell Therapy," bringing this work to an audience focused on the biological barriers to effective CAR T-cell treatment and approaches to addressing them.
Oral Presentation Details
Title: Extracellular chromatin released during CAR T-cell killing establishes a self-reinforcing resistance niche reversed by DNase I
Presenter: Alexey Stepanov, Ph.D., Institute Investigator, Department of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, United States
Publication Number: 427
Session: 702. CAR-T Cell Therapies: Basic and Translational: Overcoming Resistance and Escape in CAR-T Cell Therapy
Date: Saturday, December 12, 2026
Presentation Time: 4:00-4:15 PM Central Time
Session Time: 4:00-5:30 PM Central Time
Location: Ernest N. Morial Convention Center, Room 343-345, New Orleans, Louisiana
The 68th ASH (Free ASH Whitepaper) Annual Meeting brings together the global hematology community to share advances in research and clinical care. For more information, please visit the conference website.
(Press release, Xenetic Biosciences, NOV 4, 2026, View Source [SID1234674185])